Rye Brook, N.Y., September 14, 2021 - The U.S. Food and Drug Administration (FDA) recently approved zanubrutinib (Brukinsa®) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). This is the second therapy approved specifically for the treatment of this rare type of lymphoma. Zanubrutinib is a next-generation BTK inhibitor, which is designed to provide more targeted treatment with improved tolerability.
(Rye Brook, NY, Sept. 10, 2021) — Our top priority is — and always has been — the safety of blood cancer patients and survivors. We know that they are at increased risk of serious illness and death from COVID-19. However, up to 1 in 4 blood cancer patients won’t produce COVID-19 antibodies after vaccination, making it even more important for those around them to be vaccinated.Read More
Immune suppressing treatments - an essential component of many patient's cancer care - can blunt vaccine immune responseRead More
The Leukemia & Lymphoma Society (LLS) Named Charitable Partner of Largest Esports League in North AmericaPosted On: September 9, 2021 Read More
Every 180 Seconds, Someone in the U.S. is Diagnosed with a Blood Cancer; it’s Time to Make an Impact TogetherPosted On: September 1, 2021
(Rye Brook, NY, Sept. 1, 2021) — September is Blood Cancer Awareness Month, an opportunity to remind the public that every 180 seconds, someone in the U.S. has their life turned upside down by a blood cancer diagnosis. Read More
The following memo from Louis J. DeGennaro, Ph.D., President and Chief Executive Officer of The Leukemia & Lymphoma Society (LLS), was shared with LLS staff on Tuesday, 8/17. The email has been edited to remove internal links.Read More
Rye Brook, NY, August 10, 2021 - The U.S. Food and Drug Administration (FDA) approved loncastuximab tesirine-lpyl (ZYNLONTA) to treat adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more earlier treatments with systemic therapy including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma.Read More
FDA Approves New Treatment Option For Chronic Graft-Versus-Host-Disease In Patients Ages 12 Years And OlderPosted On: August 3, 2021
Rye Brook, N.Y., August 3, 2021 - The U.S. Food and Drug Administration (FDA) recently approved belumosudil (Rezurock™) in patients 12 years or older for the treatment chronic graft-versus-host-disease (GvHD) that has not responded or has stopped responding to earlier treatments.Read More
Please send all media-related inquiries and interview requests to firstname.lastname@example.org. An LLS representative will respond as soon as possible.